VKTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VKTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Viking Therapeutics's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. Viking Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Viking Therapeutics's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. Viking Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Viking Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.
Viking Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
The historical data trend for Viking Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viking Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Viking Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Viking Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Viking Therapeutics's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Viking Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as
Gross Profit (A: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Viking Therapeutics's Gross Profit for the quarter that ended in Dec. 2024 is calculated as
Gross Profit (Q: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Viking Therapeutics's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.00 | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Viking Therapeutics (NAS:VKTX) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Viking Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Thank you for viewing the detailed overview of Viking Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Lian | director, officer: President & CEO | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Greg Zante | officer: Chief Financial Officer | C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804 |
Marianna Mancini | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130 |
Lawson Macartney | director | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Sarah Kathryn Rouan | director | 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
J Matthew Singleton | director | 286 STANWICH ROAD, GREENWICH CT 06830 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Matthew W Foehr | director | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
Ligand Pharmaceuticals Inc | 10 percent owner | 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Hiroko Masamune | officer: Chief Development Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Michael Morneau | officer: Chief Financial Officer | C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Stephen W Webster | director | C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302 |
Rochelle Hanley | officer: Chief Medical Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
Michael Dinerman | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
From GuruFocus
By PRNewswire • 12-04-2024
By GuruFocus News • 01-06-2025
By PRNewswire • 01-08-2025
By PRNewswire • 11-19-2024
By GuruFocus News • 02-06-2025
By PRNewswire • 01-08-2025
By GuruFocus News • 03-04-2025
By PRNewswire • 11-12-2024
By GuruFocus News • 02-06-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.